Vasodynamics

What Vasodynamics does

Vasodynamics is a privately-held pharmaceutical company founded in 2020 and headquartered in London, United Kingdom. According to its stated business profile, the firm maintains a pipeline of drugs intended to prevent or mitigate the side effects associated with cancer therapy, placing it in the supportive oncology / cancer-care adjunct therapeutics niche. The company is classified as a for-profit private entity with a headcount of 11-50 employees, consistent with an early-stage biotech R&D organization.

The product portfolio, underlying technology, and revenue model are not documented in the available source data. The company's website (vasodynamics.co.uk) returned a verification/anti-bot page during data collection, and no named compounds, technology stack, customer lists, management team, pricing, or commercial milestones were disclosed. No products and services, no AI capabilities, no marketing or distribution channels, and no certifications or regulatory approvals are described in the source material.

The only confirmed commercial activity is a single funding event dated June 2021, from Longevitytech.fund, a thematic investor focused on the longevity sector, with the raised amount recorded as undisclosed. Given the absence of revenue indicators, partnered assets, or approved products in the available data, Vasodynamics operates as a pre-clinical or early-stage R&D entity that is funded by capital rather than product sales.

Name

Vasodynamics

Website

https://vasodynamics.co.uk

Company type

Private

Founded year

2020

Headcount range

1–10 employees

Short description

Vasodynamics is a London-based, privately-held pharmaceutical company developing a pipeline of drugs designed to prevent side effects associated with cancer therapy, operating as an early-stage R&D entity founded in 2020.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Oncology drug development
• Cancer supportive care
• Chemotherapy side effects
• Pharmaceutical pipeline
• Clinical stage pharma

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Core offering

Vasodynamics is a pharmaceutical company that is building a pipeline of differentiated drugs intended to prevent the side-effects associated with cancer therapy. The company is at an early development stage with no products commercially available and no specific drug candidates publicly named in the available source material.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Direct peers

• Helsinn Group: Swiss specialty pharma focused on cancer supportive care (antiemetics, mucositis). Closest comparable to Vasodynamics given its explicit focus on preventing/mitigating cancer-therapy side effects with a portfolio of differentiated drugs.
• Acacia Pharma (now part of Eagle Pharmaceuticals): Acacia was a UK-listed pure-play in oncology and post-operative supportive care (Barhemsys, Byfavo). Direct overlap with Vasodynamics on developing differentiated supportive-care drugs for cancer patients.
• PharmaMar: European oncology-focused biopharma with a pipeline that includes supportive-care and adjacent oncology assets. Comparable as another small/mid-cap European oncology drug developer.

Broad incumbents

• Mundipharma: Global specialty pharma with significant cancer-pain and supportive-care franchises. Comparable as a broader commercial player in adjacent supportive-care categories where Vasodynamics aims to compete.
• Swedish Orphan Biovitrum (Sobi): European specialty pharma focused on rare disease and specialty care, including oncology supportive care. Comparable as a larger incumbent acquiring/building differentiated supportive-care assets.
• Kyowa Kirin: Japanese specialty pharma with established oncology and supportive-care products. Comparable as a larger incumbent with commercial reach into the same supportive-care physician channels Vasodynamics would target.
• Vifor Pharma (now CSL Vifor): Specialty pharma in iron deficiency, nephrology, and supportive care. Comparable as a larger specialty player whose commercial model overlaps the supportive-care channel strategy Vasodynamics would need to build.

Regional players

• Faron Pharmaceuticals: UK-based clinical-stage biopharma developing drugs for critical care and oncology-related indications. Comparable as a London-adjacent small-cap UK pharma pursuing differentiated, niche mechanisms.
• Redx Pharma: UK-based clinical-stage oncology and fibrosis drug developer. Comparable as a fellow small UK-listed/private pharma R&D company targeting oncology pipelines with differentiated assets.

Emerging players

• Camurus: European specialty pharma using a proprietary drug-delivery platform to create differentiated long-acting formulations in oncology and supportive care. Comparable as a small/mid-cap European developer monetising differentiated formulations.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/DynamicsVaso
• LinkedInlinkedin.com/company/vaso-dynamics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vasodynamics